Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023-2024
- Author(s)
- Trinconi Cunha, M; Wallace, N; Porceddu, S; Ferrarotto, R;
- Details
- Publication Year 2025-06-01,Volume 131,Issue #11,Page e35920
- Journal Title
- Cancer
- Publication Type
- Review
- Abstract
- Antibodies against PD-1 (PD1i), such as cemiplimab and pembrolizumab, have demonstrated significant efficacy in advanced, unresectable cutaneous squamous cell carcinoma (cSCC). These agents elicit durable responses in approximately 45% of patients, contributing to improved aesthetic, functional, and survival outcomes in a subset of individuals with advanced cSCC. This review highlights recent and ongoing research investigating the safety and efficacy of immune checkpoint inhibitors for cSCC in the curative intent perioperative settings, advanced/metastatic setting, and within the immunocompromised patient populations.
- Publisher
- Wiley
- Keywords
- Humans; *Skin Neoplasms/immunology/drug therapy/therapy/pathology; *Carcinoma, Squamous Cell/immunology/drug therapy/therapy/pathology; *Immunotherapy/methods/trends; *Immune Checkpoint Inhibitors/therapeutic use/pharmacology; Antibodies, Monoclonal, Humanized/therapeutic use; Programmed Cell Death 1 Receptor/antagonists & inhibitors/immunology; PD‐1 inhibitors (PD1i); cutaneous squamous cell carcinoma; immune checkpoint inhibitors (ICI); immunosuppression; neoadjuvant
- Department(s)
- Radiation Oncology
- Publisher's Version
- https://doi.org/10.1002/cncr.35920
- Open Access at Publisher's Site
https://doi.org/10.1002/cncr.35920- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-07-17 04:27:28
Last Modified: 2025-07-17 04:28:05